During the past decade, South Georgia Medical Center/Pearlman Cancer Center conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 31 clinical trials were completed, i.e. on average, 106.9% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 18 clinical trials were completed. i.e. 600% of trials that started reached the finish line.

Out of the total clinical trials conducted in "South Georgia Medical Center/Pearlman Cancer Center" #1 sponsor was "SWOG Cancer Research Network" with 33 trials, followed by "National Cancer Institute (NCI)" with 21 trials sponsored, "Alliance for Clinical Trials in Oncology" with 4 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 4 trials sponsored and "Bristol-Myers Squibb" with 4 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "South Georgia Medical Center/Pearlman Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 44 trials as a collaborator, "Cancer and Leukemia Group B" with 9 trials as a collaborator, "SWOG Cancer Research Network" with 6 trials as a collaborator, "NCIC Clinical Trials Group" with 4 trials as a collaborator and "North Central Cancer Treatment Group" with 4 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "South Georgia Medical Center/Pearlman Cancer Center" are "Lung Cancer" (10 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Breast Cancer" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials) and "Recurrent Melanoma" (4 trials). Many other conditions were trialed in "South Georgia Medical Center/Pearlman Cancer Center" in a lesser frequency.

Most popular intervention types in "South Georgia Medical Center/Pearlman Cancer Center" are "Drug" (52 trials), "Other" (35 trials), "Biological" (26 trials), "Procedure" (7 trials) and "Radiation" (7 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (23 trials), "Quality-of-Life Assessment" (8 trials), "Nivolumab" (7 trials), "paclitaxel" (7 trials) and "Biospecimen Collection" (5 trials). Other intervention names were less common.

The vast majority of trials in "South Georgia Medical Center/Pearlman Cancer Center" are 59 trials for "All" genders, 7 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "South Georgia Medical Center/Pearlman Cancer Center". undefined are not yet recruiting, 7 are recruiting, 21 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in South Georgia Medical Center/Pearlman Cancer Center, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in South Georgia Medical Center/Pearlman Cancer Center, 1 "Phase 1" clinical trials were conducted, 26 "Phase 2" clinical trials and 39 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".